Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment

Launched by GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO · Aug 31, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how different blood-thinning treatments can help prevent blood clots in patients with multiple myeloma, a type of blood cancer. The researchers want to find out which types of these treatments—like certain medications that prevent platelets from clumping together, heparin, or oral anticoagulants—work best in reducing the risk of venous thromboembolism (VTE), which is a serious condition where blood clots form in the veins.

To join this study, participants need to be at least 18 years old and have recently been diagnosed with symptomatic multiple myeloma. They should be starting their first active treatment for the disease after signing up for the study. However, people who had blood clots in the six months before their cancer diagnosis, need a combination of blood thinners, or are already receiving treatment for multiple myeloma before the study starts cannot participate. Those who do join can expect to be monitored closely and contribute to important research that may help improve care for future patients with multiple myeloma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age equal to or greater than 18 years of age.
• • 2. New diagnosis of symptomatic MM according to the CRAB or the SLIM criteria of the International Myeloma Working Group
• • 3. First active treatment for MM started after recruitment in the study
• • 4. Signed informed consent
• Exclusion Criteria:
• • 1. Patients having had thrombosis within 6 months before diagnosis of MM
• • 2. Patients with need of combined antithrombotic regimens (i.e. VKA or DOAC or LMWK and one or two antiplatelet drugs)
• • 3. Ongoing first active treatment for MM initiated before the starting of the study.